At a glance
ClinicalIndex Comparison RecordN/ACompleted· 190 enrolled
Drug / intervention
Combinations of Oral Blood Glucose Lowering Drugsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus
In Brief
An observational study evaluating Combinations of Oral Blood Glucose Lowering Drugs for Efficacy and 2 related conditions. Completed, enrolled 190 participants across 3 sites.
Detailed Summary
Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of Ertugliflozin and Sitagliptin Con-initiation in patients with Type II Diabetes Mellitus in the Pakistani population. The study duration will be 12 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEfficacy, Safety, Tolerability
CountriesPakistan
CollaboratorsPrimary Care Diabetes Association, Pakistan
Timeline
N/ACompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartDec 2022
Primary CompletionJul 2024
Study CompletionDec 2024
TodayJul 2026
First PostedSep 27, 2022
Enrollment StartDec 1, 2022
Primary CompletionJul 1, 2024
Study CompletionDec 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.8 years ago
Interventions
Combinations of Oral Blood Glucose Lowering Drugsdrug
Combination of Ertugliflozin and Sitagliptin